Podcasts about biopsies

Turn online alignment into an offline community — join us at TheWayFwrd.com to connect with like-minded people near you. It's the best way to support this podcast and the movement we're building together: https://thewayfwrd.com/join/ Chris Crutchfield joins Alec for a conversation on how media, technology, and human physiology intersect in today's “post-truth” world. They discuss the role of video compression in deception, why physiological responses to perceived events matter more than factual accuracy, and Chris's “biopsy of a psyop” framework for understanding coordinated influence campaigns. For more details, links, timestamps and resources mentioned in this episode, visit our website: https://thewayfwrd.com/podcast/ep-194-the-biofield-the-internet-of-psyops-with-chris-crutchfield/ Resources and Links Instagram - https://instagram.com/67podcast  YouTube - https://www.youtube.com/@sixsevenpodcast  “Biopsy of a Psyop, See”  Map – https://67podcast.short.gy/BiopsyMap  Campsite - https://campsite.bio/67podcast  Related Links & References What If My Body is Brilliant? — https://www.youtube.com/watch?v=Jhv2b5auS3c  Sabrina Wallace — https://odysee.com/@Psinergy:a  The End of Covid — https://music.amazon.com/es-us/podcasts/7b17bf72-7017-4f5a-812f-680eaf96174f/episodes/ba1b9073-a3fd-4998-8beb-5090dc01b3fd/the-collective-resistance-podcast-discussing-the-end-of-covid-w-alec-zeck    The Way Forward podcast is sponsored by: New Biology Clinic: Redefine Health from the Ground Up Experience tailored terrain-based health services with consults, livestreams, movement classes, and more. Visit https://NewBiologyClinic.com and use code TheWayForward for $50 off activation. Way Forward members get the fee waived: https://thewayfwrd.com/membership-sign-up/ ————————— RMDY Collective: Homeopathy Made Accessible High-quality remedies and training to support natural healing. Enroll: https://rmdyacademy.org/?bg_ref=MKho6KZowaExplore: https://rmdycollective.org/?bg_ref=MKho6KZowa —————————  

In this groundbreaking episode, we dive deep into MOJO Health's "Data Iceberg" concept that's revolutionizing cancer care. Many people make life-changing medical decisions using only 2 types of data - biopsy results and imaging scans. If you go to the most advanced cancer centers, you likely use 6, but there are 7 additional categories of health data hiding beneath the surface that will transform your healing strategy.What You'll Discover:- Why most healthcare operates on "tip of the iceberg" data- The 13 hidden data categories that predict treatment success- How molecular DNA profiling creates personalized treatment roadmaps- The power of circulating tumor DNA (liquid biopsies) for real-time monitoringPerfect for: Cancer patients, survivors, caregivers, healthcare advocates, and anyone who wants to transform from reactive to proactive healthcare.Remember: Data G's don't just hope their treatment is working. They know.Resources Mentioned:For our downloadable Guide to Be a Data G, please go to mojohealth.org/datagguideTo set up an appointment with Oscar Sierra, please reach out to https://www.sierracollaborativemed.com/To see National Cancer Institute's page the blood biomarkers: https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-listAnd here for information on different types of data to request: https://www.mojohealth.org/be-a-data-g-1Other Podcasts to watch:#4 A Data G's Guide to Beating Cancer w/ Julie Stevens and Oscar Sierra, L.Ac.#6 BRCA2 Data Dilemma: Lessons in Gene Expression#8 How Genomic Testing Can Transform Your Cancer JourneyWhat tests do you need your doctor to order? Biopsy, Imaging, Circulating Tumor DNA, and Molecular DNA of the Tumor.Basically everything else you can order on your own through Direct Patient Labs: https://www.mojohealth.org/direct-labs-mojo-panelsConnect with Julie Stevens and the MOJO Movement: Instagram: https://instagram.com/mojohealthorg TikTok: https://tiktok.com/@julie.stevens97YouTube: https://www.youtube.com/@mojohealth Facebook: https://facebook.com/mojohealthorg Website: https://www.mojohealth.org/DISCLAIMER: The views, thoughts, and opinions expressed on this podcast are the speaker's own and do not represent the views, thoughts, and opinions of MOJO Health Cooperative LLC, a Georgia Limited Liability Company, its respective officers, directors, employees, agents, or representatives. This podcast is presented by MOJO Health Cooperative, and cannot be copied or rebroadcast without consent. The material and information presented here is for general information purposes only, and not intended to supplant the expert advice and/or consultation of a medical doctor and/or a licensed physician, and/or an attorney. In short, this podcast is not intended to replace professional medical advice, nor legal advice. The "MOJO Health" name and all forms and abbreviations are the property of its owner and its use does not imply endorsement of or opposition to any specific organization, product, or service. Again, none of the content of this podcast should be considered legal advice, nor medical advice. As always, consult a lawyer and/or a licensed physician in lieu of relying upon the advice of any of the participants of this podcast. The host(s) of this podcast are not licensed lawyers, physicians, doctors of osteopath, nor medical doctors in any jurisdiction anywhere. The host(s) of this podcast do not practice medicine and do NOT profess to be able to do any of the following: (1) diagnose, heal, treat, prevent, prescribe for, or removing any physical, mental, or emotional ailment or supposed ailment of an individual; (2) engage in the end of human pregnancy; (3) treat human ailments; nor (4) perform acupuncture. MOJO Health Cooperative LLC is not responsible for any losses, damages, or liabilities that may arise from the use of this podcast.

In this episode of TGen Talks, we sit down with three researchers who are working to make cancer care safer and more precise for some of the most vulnerable patients—children with rare brain tumors. Dr. Floris Barthel, Dr. Shea Gallus, and graduate student Sharvari Mankame are part of a team at TGen and Phoenix Children's Hospital exploring liquid biopsies—a method that uses small samples of blood or spinal fluid to detect and monitor brain cancer. This approach could reduce the need for invasive surgeries, which are especially hard on young patients. Our guests explain how liquid biopsies work, what they're learning from genetic markers called K-mers, and how artificial intelligence is helping them analyze tumor DNA in ways that weren't possible before. Their goal is to find a better way to track cancer in real time—giving doctors more information while easing the burden on patients and families. While this science is still developing, it's already showing real potential to shift how we approach diagnosis and treatment—not just in pediatrics, but across cancer care.

As always, you bring the best questions for these grab bag episodes. Today, we cover dog autoimmune diseases (though cats find their way to make it in a bit). How do you tell the difference between DLE and PF?What if an owner can't biopsy the case?How do you treat SLO? Sebaceous adenitis?Find the answers to these questions and more on this week's episode of The Derm Vet podcast!00:00 Intro01:30 SLO & sabaceous adenitis09:40 Steroids and Autoimmune diseases12:23 What to do when owners can't biopsy the case15:12 Pemphigus foliaceus in Dogs16:05 Pemphigus foliaceus in Cats17:07 Autoimmune Disease vs Allergies18:31 Differentiating between DLE and Pemphigus Exfoliation in dogs21:48 Outro

Prostate cancer deaths have been climbing over the last decade in part due to confusion over who should be screened and treated. In part 1 of a three-part series on prostate cancer, host Sandra Lindsay speaks with Samir Taneja, MD, a trailblazer in urologic cancer innovation, to explore how modern diagnostics and treatments, such as the groundbreaking use of MRI technology, are transforming patient outcomes. As Northwell's senior vice president and system chair of urology, Dr. Taneja provides invaluable insights into the shifting landscape of prostate cancer care and the critical importance of early detection. Tune in to understand the vital steps needed to increase awareness and save lives. About Northwell Health Northwell Health is New York State's largest healthcare provider and private employer, with 21 hospitals, 850 outpatient facilities and more than 16,600 affiliated physicians. We're making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We're training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies. For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. Get the latest news and insights from our experts in the Northwell Newsroom: Press releases Insights Podcasts Publications Interested in a career at Northwell Health? Visit http://bit.ly/2Z7iHFL and explore our many opportunities. Get more expert insights from leading experts in the field — Northwell Newsroom.  Watch episodes of 20-Minute Health Talk on YouTube.  For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. Interested in a career at Northwell Health? Visit the health system's job portal and explore our many opportunities.    

Blind biopsies leave questions unanswered. In this episode of BackTable OBGYN, host Dr. Mark Hoffman welcomes back Dr. Linda Bradley, an expert in obstetrics, gynecology, and hysteroscopy from the Cleveland Clinic, to discuss the benefits and advancements of direct visualized endometrial sampling over traditional blind biopsy techniques. ---This podcast is supported by:Medtronichttps://www.medtronic.com/en-us/healthcare-professionals/specialties/gynecology/product-portfolio.html---SYNPOSISDr. Bradley emphasizes the importance of hysteroscopy for accurate diagnosis and treatment of various gynecological issues, including abnormal uterine bleeding. They explore the limitations of blind biopsies and the advantages of hysteroscopy in detecting focal lesions, avoiding unnecessary hysterectomies, and ensuring patient safety. The discussion also touches on the economic and procedural challenges in adopting hysteroscopy more widely in clinical practice.---TIMESTAMPS00:00 - Introduction 03:30 - The Evolution of Hysteroscopy at Cleveland Clinic04:49 - Challenges and Innovations in Hysteroscopy06:30 - Clinical Insights: Direct Visualized Endometrial Sampling12:03 - Case Studies and Practical Applications15:46 - The Importance of Visual Examination in Gynecology20:03 - Advocating for Hysteroscopy in Medical Practice31:07 - Patient History and Trauma Considerations31:34 - Cancer Detection and Missed Diagnoses32:14 - Challenges with Unscheduled Bleeding32:56 - Case Study: Blood Transfusions and Hysterectomy33:38 - Importance of Hysteroscopy34:43 - Hysteroscopy Techniques and Best Practices37:41 - Ultrasound and SIS (Saline Infusion Sonohysterography) for Imaging38:45 - Post-Operative Care and Follow-Up47:41 - Environmental and Economic Considerations in Healthcare52:51 - Final Thoughts and Patient Advocacy

Liquid biopsy is breaking speed and access barriers in precision oncology. In this episode of the Precision Medicine Podcast, part of our series Bringing Precision Medicine to Everyone and the first in a two-part focus, founder and host Karan Cushman speaks with Dr. Kashyap Patel, CEO of Carolina Blood and Cancer Care Associates, author, and national leader in value-based oncology.Together, they explore how liquid biopsy is changing the diagnostic and treatment landscape. This blood-based test can deliver results in days, be repeated as needed, and reduce the need for invasive procedures. Tissue biopsy remains important, but when the samples are too small or unsuitable for testing, liquid biopsy provides a valuable alternative in guiding treatment decisions and monitoring disease.For patients with aggressive “turbo cancers” such as diffuse large B-cell lymphoma or small cell lung cancer, the time saved can be lifesaving. Karan shares her own experience with DLBCL, while Dr. Patel highlights real-world cases where liquid biopsy revealed actionable mutations, informed therapy, or enabled minimal residual disease (MRD) monitoring.Finally, Dr. Patel underscores the need for standardization and payer alignment to move liquid biopsy from innovation to everyday practice. This candid discussion frames liquid biopsy not as a futuristic idea, but as a clinically powerful and scalable tool that is closing gaps in precision oncology today.

In this Episode which marks the 5th anniversary of the Penis Project Podcast, Kate and Melissa, practitioners from Restorative Health Clinic talk to Kirk (59), who shares his very recent journey with prostate cancer — from vigilant PSA screening due to a strong family history, through biopsy and robotic prostatectomy(Gleason 9), to an unusually swift return of continence and erections (yes, really… at 5 weeks!). We chat about why a good GP relationship matters, common myths (no, PSA screening is not a finger-up-the-bum), and practical rehab steps that set you up for the best outcome. We also touch on the challenges recent Medicare telehealth changes pose for rural men and why community conversations save lives.  Key Takeaways:     PSA screening saves lives: It's a blood test. Many men still believe screening means a rectal exam — that misconception stops blokes from testing.  Early and regular checks matter, especially with family history. Kirk and his GP were “on it,” which likely changed his trajectory.  Rehab starts before surgery: Pre-op pelvic floor coaching and early, structured penile rehab support faster continence and sexual recovery.  Expectations matter: Being clear about how important sex is to you helps the team tailor a plan (medications, devices, or injections) so intimacy continues post-treatment.  Modern prostate cancer care is not what it was 20 years ago — minimally invasive surgery, targeted radiation, and better side-effect profiles.  Episode Highlights  Family history matters: Kirk, a 59-year-old anaesthetist, always knew prostate cancer was a “when, not if.” Vigilant PSA screening caught it early.  PSA test = blood test: Many men still mistakenly think screening means a rectal exam — this myth stops blokes from testing.  Gleason upgrade: Biopsy showed 7, but post-surgery pathology was 9 — reinforcing why early surgery was lifesaving.  GPs are gold: A trusted GP relationship ensures timely checks and continuity of care.  Rehab starts before surgery: Pelvic floor exercises and penile rehab education gave Kirk the best start.  Fast recovery: At 5 weeks post-op, Kirk is dry, pad-free, and already regaining erectile function with support strategies.  Community conversations: Kirk shared his diagnosis with ice-hockey teammates — most had no idea PSA was just a blood test.  Rural barriers: Medicare telehealth changes risk limiting access for country men as of November 1st 2025 — highlighting the importance of policy that supports remote care.  Positive outlook: Kirk's story proves recovery can be quicker than many expect, and modern treatments offer far better outcomes than in the past.  Take-home message: Don't wait for symptoms — get your PSA blood test done and talk to your mates about it.  Shareable quotes  “Good news — PSA screening is a blood test. That's it.”  “Pre-hab matters: start pelvic floor and penile rehab before surgery.”  “Sex after prostate cancer is absolutely possible — the toolkit is bigger and better than ever.”  “Men will talk footy all day — let's talk our health the same way.”    Resources & Links:  Book a telehealth consult with our sexual health nurse practitioners at Restorative Health Clinic  For more information check out our websites www.rshealth.com.au , www.makehardeasy.com.au and www.melissahadleybarrett.com  Listen & Subscribe  If you found this episode helpful, don't forget to subscribe, rate, and review the podcast! Your feedback helps us continue bringing important conversations to light. Search for The Penis Project Podcast on Spotify, Apple Podcasts, or your favourite podcast app.  Connect With Us  We love hearing from real people, navigating penile health. If you'd like to share your journey or ask a question, get in touch.     Email: admin@rshealth.com.au    Websites:  https://rshealth.com.au/  All genders  https://makehardeasy.com.au   https://melissahadleybarrett.com   Instagram:  https://www.instagram.com/melissahadleybarrett/  https://www.instagram.com/restorativehealth.clinic/    YouTube: https://www.youtube.com/@melissahadleybarrett   TikTok: @melissahadleybarrett    Facebook:  https://m.facebook.com/p/Melissa-Hadley-Barrett-100085237672685/  https://www.facebook.com/profile.php?id=100085146627814    Linkedin:  https://www.linkedin.com/in/melissa-hadley-barrett/   TEDX  https://www.youtube.com/watch?v=IjHj1YTmLoA     

In this new episode of Speaking of SurgOnc, Dr. Rick Greene discusses with Dr. Faina Nakhlis the upgrade rate to ductal carcinoma in situ or invasive cancer following excision for patients diagnosed with flat epithelial atypia on core biopsy, as reported in the article, "Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or Ductal Carcinoma In Situ in Patients Diagnosed with Flat Epithelial Atypia by Core Needle Biopsy (TBCRC 034).”

Host Dr. Amanda Redfern welcomes Dr. Claudia Prospero Ponce, a neuro-ophthalmologist and ocular pathologist, to share her unique perspective on how to diagnose giant cell arteritis (GCA) when temporal artery biopsies are not classically positive.  For more information about pathological markers in GCA, check out this paper referenced in the episode: Sultan H, Smith SV, Lee AG, Chévez-Barrios P. Pathologic Markers Determining Prognosis in Patients With Treated or Healing Giant Cell Arteritis. Am J Ophthalmol. 2018;193:45-53. For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Rethinking prostate care begins with one powerful question: are biopsies always necessary or is there a better way to protect both life and vitality?In this episode, Dr. Stephen Petteruti speaks directly to those who value longevity and proactive health. He walks through compelling data from studies like TOAD, CHAARTED, STAMPEDE, and PEACE-1, showing that aggressive prostate cancer treatments often offer little survival benefit.Dr. Stephen doesn't advocate ignoring abnormal PSA or MRI results. Instead, he encourages you to ask smarter questions about your care. He outlines practical steps for non-invasive monitoring and decision-making that prioritizes long-term health.If you or someone you care about is navigating prostate care, tune into the full episode of Metastatic Disease: Why Prostate Biopsies Can Do More Harm Than Good.Enjoy the podcast? Subscribe and leave a 5-star review on your favorite platforms.Dr. Stephen Petteruti is a leading Functional Medicine Physician dedicated to enhancing vitality by addressing health at a cellular level. Combining the best of conventional medicine with advancements in cellular biology, he offers a patient-centered approach through his practice, Intellectual Medicine 120. A seasoned speaker and educator, he has lectured at prestigious conferences like A4M and ACAM, sharing his expertise on anti-aging. His innovative methods include concierge medicine and non-invasive anti-aging treatments, empowering patients to live longer, healthier lives.Website: www.intellectualmedicine.com Website: https://www.theprostateprotocol.com/ YouTube: https://www.youtube.com/@intellectualmedicine LinkedIn: https://www.linkedin.com/in/drstephenpetteruti/ Instagram: instagram.com/intellectualmedine Consultation: https://www.theprostateprotocol.com/book-a-consultation Store: https://www.theprostateprotocol.com/store Community: https://www.theprostateprotocol.com/products/communities/v2/fightcancerlikeaman/home    Disclaimer:  The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.Produced by https://www.BroadcastYourAuthority.com 

The FDA has endorsed vibration-controlled transient elastography as a surrogate endpoint for MASH trials, marking the first non-invasive alternative to liver biopsy. A Japanese cohort study linked breakfast skipping and late dinners to higher fracture risk, with combined habits raising risk by nearly 25%. Finally, a global meta-analysis suggests shingles vaccination reduces major cardiovascular events by ~16–18%, though most evidence is observational.

Dr. Shravan Sridhar explores the evidence-based approach to transthoracic needle biopsy, covering indications, performance metrics, complications, and risk mitigation strategies. Listeners will gain practical insights on patient selection, technical considerations, and navigating controversial scenarios to optimize outcomes in clinical practice. Evidence-based Approach to Transthoracic Needle Biopsy: Procedural Techniques, Risks, and Controversies. Sridhar et al. RadioGraphics 2025; 45(9):e240094.

In this episode, hosts Drs. Peter Lu and Jason Silverman talk to Dr. Justine Turner about a non-biopsy approach to diagnosis for celiac disease in children. Dr. Turner is a Professor of Pediatrics and Divisional Director for the Division of Gastroenterology and Nutrition at the University of Alberta and also the medical lead for the Multidisciplinary Pediatric Celiac Disease Clinic at Stollery Children's Hospital in Edmonton. Learning Objectives:Review current clinical guidelines for the diagnosis of celiac disease in childrenUnderstand the potential pros and cons of a non-biopsy approach to diagnosis for celiac diseaseRecognize the potential impacts of serologic diagnosis for celiac disease on patients, their families and healthcare systemsLinks (to be added!!):Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and NutritionNASPGHAN Clinical Report on the Diagnosis and Treatment of Gluten-related DisordersEuropean Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020Positive Predictive Value of Tissue Transglutaminase IgA for Celiac DiseaseSupport the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

Send us a text00:00:00 - Surf's Up: Season 6 Episode 13 Louise Campbell, Jörn Schattenberg and Roger Green continue their discussion of some major issues from earlier this year, while co-authors Aleksander Krag and Stine Johanset join Roger to discuss their recent publication in The Lancet, titled "Screening for Advanced Liver Disease." 00:04:45 - Major Issues of the First Six Months: Integrated Patient ManagementLouise drives this conversation based on two related issues she sees emerging: (i) increasing opportunities for motivated patients to manage their own health and (ii) managing the total patient in an environment where people may be taking incretin agonists as if they are consumer drugs. With increased access to scanning, providers can monitor patients (and patients can self-monitor) more closely. However, some of the issues a provider might find are tricky: patients who undertake what Louise describes as "the sneaky areas patients think are normal, but are probably contributing to disease" due to miseducation or no education on healthy eating and lifestyle, or patients purchasing and using incretin agonists through consumer channels, but possibly at subtherapeutic doses. Vigilance and probing are key here, but health systems will need to train more people on the types of probing that uncover underlying issues and behaviors that patients mistakenly believe to be healthy. 00:21:02 - Newsmakers: Aleksander Krag and Stine Johansen discuss Screening for Advanced Liver DiseaseLast month, The Lancet posted online an article from Stine Johansen, Fredrik Åberg, Emmanuel Tsochatzis and Aleksander Krag, titled "Screening for Advanced Liver Disease." The article aims to update the Wilson and Jungner criteria, originally developed in 1960, to address modern needs and issues. In this conversation, Professor Krag and Dr. Johansen join Roger Green to discuss their article. There are many nuances and high points to cover in this thoughtful, fairly lengthy conversation, but the key point is that screening a mass population for HCC or cirrhosis has an entirely different set of issues and criteria compared to the screening usually discussed on this podcast, which involves identifying a population at increased risk for MASLD or MASH and screening them. 00:54:42 - Major Issues of the First Six Months: Changes in US Health Policy and Potential for Dynamism in the In-Office Scanning Market Roger drives this conversation, focusing on two very different, yet very important issues: the first is the increasing dynamism of the in-office scanning market, with leader Echosens developing new products and services, while companies like e-Scopics, Sonic Incytes, and Mindray (Hepatus) are introducing new devices with competing profiles. Roger discusses the idea that some scanners keep all data resident in the machine, while others send it immediately to the cloud. Louise suggests that we should welcome any reliable scanning device to the market. Separately, he lists some concerns about how the Trump Administration's focus on cutting services to the poor, coupled with Robert F. Kennedy Jr.'s distrust of pharmaceuticals and mainstream health research, might limit the number of Americans with access to healthcare and the kinds of care they can access. At the end of this conversation, Roger asks Jörn and Louise what they consider major issues for the next six months.01:11:40 - Business Report and Wrap-Up

Send us a textAI Pathology & Genomics: A New Benchmark for Predicting Gene MutationsIf you still think visual quantification is “good enough” in pathology, think again. In this 27th episode of DigiPath Digest, I break down four transformative abstracts that show how AI is shifting our diagnostic landscape—from breast cancer segmentation to fibrosis assessment, and all the way to spatial immunology and the evolving immunoscore.If you're still relying on manual scoring, static staging systems, or single-marker immunohistochemistry, this episode will challenge you to look deeper—literally and algorithmically.

Liquid Biopsies: A Breakthrough Technology in Cancer Research & Clinical Practice with guest Dr. Heather Parsons August 17, 2025 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

Synopsis: Some of the most game-changing ideas in healthcare come from unexpected intersections—where engineering meets biology, and where data meets patient urgency. This episode of Biotech 2050 dives into that exact convergence with a look at how one visionary leader helped pioneer blood-based cancer diagnostics. Co-CEO & Co-Founder of Guardant Health, AmirAli Talasaz, shares the story behind building one of biotech's most impactful companies. From a graduate student navigating genomics for the first time to raising over $3 billion and leading a public company, he reflects on lessons learned, obstacles faced, and what it takes to create a patient-first culture at scale. The conversation explores the technology behind liquid biopsies and companion diagnostics, the challenges of insurance reimbursement, and how Guardant's innovations are helping detect recurrence and screen for early-stage cancers—all through a simple blood test. Hosted by Biotech 2050 Co-Founder Rahul Chaturvedi, this episode is packed with insights on biotech leadership, pharma partnerships, and building a company that scales with both urgency and heart. Biography: AmirAli Talasaz is the co-CEO of the leading precision oncology company, Guardant Health, which he co-founded in 2012 with Helmy Eltoukhy. Prior to co-founding Guardant Health, he was senior director of Diagnostics Research at Illumina and led the efforts for emerging clinical applications of next-generation genomic analysis. Before Illumina, he founded Auriphex Biosciences, which focused on purification and genetic analysis of circulating tumor cells for cancer management. Talasaz received his PhD in electrical engineering and MSc in management science from Stanford University.

World renowned, New York Times bestselling author, Joel Fuhrman, MD, has been sharing evidence-based research about healing our bodies with a Nutritarian lifestyle. There is such a powerful connection between a plant-based diet and cancer prevention. Dr. Fuhrman goes beyond nutrition to address an often-overlooked topic: the risks and realities of conventional cancer screenings. From […]

The FiltrateJoel Topf Bluesky: @kidneyboy.bsky.social‬AC @medpeedskidneys.bsky.social‬Nayan Arora @captainchloride.bsky.social‬Special Guest Vandana Niyyar Professor of Medicine at Emory School of MedicineEditing byNayan AroraThe Kidney Connection written and performed by by Tim YauShow NotesAmerican Society of Diagnostic and Interventional Nephrology (Website)ASDIN List of training sitesPlacement, performance and complications of the Ash Split Cath hemodialysis catheter (PubMed)Platelet Function Assay FAQ (PDF)Saint Clair's Vascular Access Center where we do outpatient biopsies (Website)The studies: NephJC Summary Prasad Study KI Reports Chakrabarti in Kidney 360Thromboelastogram (TEG) (Life in the Fastline)Elastigirl (Wikipedia)Association of Kidney Biopsy Needle Gauge with Post-Procedure Complications and Biopsy Adequacy (PubMed)Complications of Percutaneous Renal Biopsy (PubMed)Tubular SecretionsNayan Quarterback on Netflix (Wikipedia)AC The Rehearsal on HBO (Wikipedia)Joel The Detroit Tigers (MLB)

Crystal goes to the dermatologist and shares medicine's latest epic fail. She also shamelessly promotes her new Medium page https://medium.com/@moremorgellons/the-parasite-pretending-to-be-alive-dispatches-from-under-my-fingernails-59c6e4ca5ce1

July 25, 2025 In this episode, Scott, Mark, and Ray answer coding questions submitted through the PRS Help Desk. 1) Payor: MedicareState: FLCode/Codes: 52353-52 and 52332-59-51Catagory: Kidney StonesQuestion: If I have to abort a planned ureteroscopy and laser lithotripsy because the UO is too narrow to pass the ureteroscope so I place a stent. Can I bill the 52353-52 and 52332-59-512) Can you clarify what documentation is required to be able to code 51729? Is the length of the urethra required to be documented or is it just a possible element?The AUA policy & Advocacy brief for Urodynamcis shows the example documentation of the UPP as, “ Urethreal Pressue Profile: The maximum urethral pressue profile was 45 cm of water with a functional urethral lenght of 2.75 cm. At 200cc, coughing was iniitated. There was no demonstrable leak of urine at 117 cm of water with abdominal straining.”My provider is only documenting: Leak point pressure testing: volume tested: 150mL, Stress Induced DO: Absent Valsalva Leak Point Pressure: No Leak.Is that enough to capture 51729?Thank you for your assistance! 3) Can you tell me the best way to document and correctly bill for prostate biopsy using 55700/76942 and 76872?  I am told we are no longer getting paid for those.4) What is the best way to document and code for placement of fiduciary markers under US guidance?Thanks in advancePRS Coding and Reimbursement HubAccess the Hub Free Kidney Stone Coding CalculatorDownload NowPRS Coding CoursesFor UrologistFor APPsFor Coders, Billers, and AdminsPRS Billing and Other Services - Book a Call with Mark Painter or Marianne DescioseClick Here to Get More Information and Request a Quote Join the Urology Pharma and Tech Pioneer GroupEmpowering urology practices to adopt new technology faster by providing clear reimbursement strategies—ensuring the practice gets paid and patients benefit sooner.https://www.prsnetwork.com/joinuptp Click Here to Start Your Free Trial of AUACodingToday.com   The Thriving Urology Practice Facebook group.The Thriving Urology Practice Facebook Group link to join:https://www.facebook.com/groups/ThrivingPractice/ 

Sheng Zhong, Ph.D. pioneers technologies that advance women's reproductive health. Zhong develops a minimally invasive method to analyze extracellular RNA secreted by embryos during IVF. By sequencing tiny samples of spent culture media, they generate comprehensive RNA profiles and use machine learning to identify biomarkers that predict embryo quality with accuracy comparable to traditional imaging. This breakthrough offers a gentler, data-driven alternative for assessing embryo viability, with the potential to improve live birth rates and support families navigating infertility. Zhong's research highlights the power of molecular innovation to transform fertility care and address critical challenges in women's health. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40676]

Sheng Zhong, Ph.D. pioneers technologies that advance women's reproductive health. Zhong develops a minimally invasive method to analyze extracellular RNA secreted by embryos during IVF. By sequencing tiny samples of spent culture media, they generate comprehensive RNA profiles and use machine learning to identify biomarkers that predict embryo quality with accuracy comparable to traditional imaging. This breakthrough offers a gentler, data-driven alternative for assessing embryo viability, with the potential to improve live birth rates and support families navigating infertility. Zhong's research highlights the power of molecular innovation to transform fertility care and address critical challenges in women's health. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40676]

Sheng Zhong, Ph.D. pioneers technologies that advance women's reproductive health. Zhong develops a minimally invasive method to analyze extracellular RNA secreted by embryos during IVF. By sequencing tiny samples of spent culture media, they generate comprehensive RNA profiles and use machine learning to identify biomarkers that predict embryo quality with accuracy comparable to traditional imaging. This breakthrough offers a gentler, data-driven alternative for assessing embryo viability, with the potential to improve live birth rates and support families navigating infertility. Zhong's research highlights the power of molecular innovation to transform fertility care and address critical challenges in women's health. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40676]

Sheng Zhong, Ph.D. pioneers technologies that advance women's reproductive health. Zhong develops a minimally invasive method to analyze extracellular RNA secreted by embryos during IVF. By sequencing tiny samples of spent culture media, they generate comprehensive RNA profiles and use machine learning to identify biomarkers that predict embryo quality with accuracy comparable to traditional imaging. This breakthrough offers a gentler, data-driven alternative for assessing embryo viability, with the potential to improve live birth rates and support families navigating infertility. Zhong's research highlights the power of molecular innovation to transform fertility care and address critical challenges in women's health. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40676]

Sheng Zhong, Ph.D. pioneers technologies that advance women's reproductive health. Zhong develops a minimally invasive method to analyze extracellular RNA secreted by embryos during IVF. By sequencing tiny samples of spent culture media, they generate comprehensive RNA profiles and use machine learning to identify biomarkers that predict embryo quality with accuracy comparable to traditional imaging. This breakthrough offers a gentler, data-driven alternative for assessing embryo viability, with the potential to improve live birth rates and support families navigating infertility. Zhong's research highlights the power of molecular innovation to transform fertility care and address critical challenges in women's health. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40676]

Is a prostate biopsy protecting your health or putting it at risk?In this episode, Dr. Stephen Petteruti challenges everything you thought you knew. He exposes the hidden dangers of prostate biopsies: how they can spread cancer, lead to half-answers, and trap men in unnecessary treatments.Dr. Stephen breaks down smarter, safer alternatives like MRIs and biomarkers. And if you've already had a biopsy, he shares a clear path forward to protect your vitality, not just chase numbers.Rethink your options. Take back control. Your health deserves the full picture.Tune into the full episode of Prostate Biopsy: Why You Might Regret Getting One—and What to Do If You Already Did.Enjoy the podcast? Subscribe and leave a 5-star review!Dr. Stephen Petteruti is a leading Functional Medicine Physician dedicated to enhancing vitality by addressing health at a cellular level. Combining the best of conventional medicine with advancements in cellular biology, he offers a patient-centered approach through his practice, Intellectual Medicine 120. A seasoned speaker and educator, he has lectured at prestigious conferences like A4M and ACAM, sharing his expertise on anti-aging. His innovative methods include concierge medicine and non-invasive anti-aging treatments, empowering patients to live longer, healthier lives.Website: www.intellectualmedicine.com Website: https://www.theprostateprotocol.com/ YouTube: https://www.youtube.com/@intellectualmedicine LinkedIn: https://www.linkedin.com/in/drstephenpetteruti/ Instagram: instagram.com/intellectualmedine Consultation: https://www.theprostateprotocol.com/book-a-consultation Store: https://www.theprostateprotocol.com/store Community: https://www.theprostateprotocol.com/products/communities/v2/fightcancerlikeaman/home  Disclaimer:  The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.Produced by https://www.BroadcastYourAuthority.com

Prostate biopsy is evolving rapidly, offering urologists more precision - but also more decisions. In this episode of BackTable Urology, Dr. Ricardo Sánchez-Ortiz, a pioneer in robotic surgery and neuro-urology in Puerto Rico, joins host Dr. Jose Silva to discuss the shifting landscape of prostate biopsy and emerging strategies that improve accuracy and personalize care. --- SYNPOSIS The conversation explores the transition from transrectal to transperineal prostate biopsy, emphasizing the role of PSA density and modern imaging in refining patient selection. Dr. Sánchez-Ortiz highlights the value of biomarkers in improving diagnostic accuracy and focal therapy as a promising, less invasive treatment option.Beyond clinical innovations, the doctors also discuss the importance of communication in urology practice. Dr. Sánchez-Ortiz shares how tools like WellPrept can enhance patient education and engagement, reinforcing the need for individualized care strategies in an increasingly complex diagnostic landscape. --- TIMESTAMPS 00:00 - Introduction 02:14 - Evolution of Prostate Biopsy Methods17:51 - Transperineal vs. Transrectal Approaches22:52 - Use of Sedation35:10 - PSA Screening41:48 - Rise in Metastatic Prostate Cancer50:44 - Potential of Focal Ablation55:58 - Use of WellPrept --- RESOURCES WellPrept:https://www.wellprept.com/

Dr. Samuel Washington presents an in-depth overview of prostatectomy, a surgical option for treating prostate cancer confined to the prostate gland. He explains how robotic-assisted laparoscopic surgery allows for precise removal of the prostate and seminal vesicles while minimizing recovery time and hospital stay. Washington discusses the importance of imaging, biopsy results, and patient risk levels in guiding decisions about lymph node removal and nerve-sparing techniques. He emphasizes realistic expectations around recovery, including urinary incontinence and erectile dysfunction, and outlines strategies for managing these outcomes, such as rehabilitation programs and medication. He also addresses the anatomical changes caused by surgery and the impact on fertility and sexual function. Emerging technologies aim to further improve surgical precision and cancer removal. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40802]

Dr. Samuel Washington presents an in-depth overview of prostatectomy, a surgical option for treating prostate cancer confined to the prostate gland. He explains how robotic-assisted laparoscopic surgery allows for precise removal of the prostate and seminal vesicles while minimizing recovery time and hospital stay. Washington discusses the importance of imaging, biopsy results, and patient risk levels in guiding decisions about lymph node removal and nerve-sparing techniques. He emphasizes realistic expectations around recovery, including urinary incontinence and erectile dysfunction, and outlines strategies for managing these outcomes, such as rehabilitation programs and medication. He also addresses the anatomical changes caused by surgery and the impact on fertility and sexual function. Emerging technologies aim to further improve surgical precision and cancer removal. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40802]

Dr. Samuel Washington presents an in-depth overview of prostatectomy, a surgical option for treating prostate cancer confined to the prostate gland. He explains how robotic-assisted laparoscopic surgery allows for precise removal of the prostate and seminal vesicles while minimizing recovery time and hospital stay. Washington discusses the importance of imaging, biopsy results, and patient risk levels in guiding decisions about lymph node removal and nerve-sparing techniques. He emphasizes realistic expectations around recovery, including urinary incontinence and erectile dysfunction, and outlines strategies for managing these outcomes, such as rehabilitation programs and medication. He also addresses the anatomical changes caused by surgery and the impact on fertility and sexual function. Emerging technologies aim to further improve surgical precision and cancer removal. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40802]

Dr. Samuel Washington presents an in-depth overview of prostatectomy, a surgical option for treating prostate cancer confined to the prostate gland. He explains how robotic-assisted laparoscopic surgery allows for precise removal of the prostate and seminal vesicles while minimizing recovery time and hospital stay. Washington discusses the importance of imaging, biopsy results, and patient risk levels in guiding decisions about lymph node removal and nerve-sparing techniques. He emphasizes realistic expectations around recovery, including urinary incontinence and erectile dysfunction, and outlines strategies for managing these outcomes, such as rehabilitation programs and medication. He also addresses the anatomical changes caused by surgery and the impact on fertility and sexual function. Emerging technologies aim to further improve surgical precision and cancer removal. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40802]

In today's episode, we had the opportunity to speak with Henry M. Kuerer, MD, PhD, FACS, CMQ, about the potential to safely omit surgery in a subset of patients with early-stage HER2-positive or triple-negative breast cancer who achieve a pathologic complete response (pCR) following neoadjuvant systemic therapy. Dr Kuerer is a professor of breast surgical oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. In our conversation, Dr Kuerer reviewed the rationale behind a prospective phase 2 clinical trial (NCT02945579) testing image-guided vacuum-assisted core biopsy to identify patients with no residual disease after neoadjuvant therapy. He outlined the strict technical and eligibility criteria that enabled accurate detection of pCR—including tumors downsizing to less than 2 cm and biopsy of at least 12 cores from the tumor bed—and discussed why this biopsy-based approach may be more reliable than standard surgery in detecting residual disease. He also highlighted the broader clinical implications of the findings, noting that patients with biopsy-confirmed pCR may proceed directly to radiotherapy and avoid breast surgery altogether.

Host: Darryl S. Chutka, M.D. Guests: Darrell S. Pardi, M.D., and Laura E. Raffals, M.D. Microscopic colitis is one of the lesser-known members of the inflammatory bowel disease family. Symptoms include chronic, frequent diarrhea and fecal urgency. It's usually suspected from the patient's clinical symptoms and diagnosis is established by colonoscopy with biopsy. Biopsy is necessary as the colonic mucosa appears normal at endoscopy. A specific cause isn't known but it can be associated with several medications. Although it's not typically a life-threatening condition, it can lead to weight loss and potentially dehydration. How does microscopic colitis differ from ulcerative colitis or Crohn's Disease? Who's at risk of developing it? Since these patients usually present to primary care providers, when should we suspect it? How is it managed, and can it be cured?  These are some of the questions I'll be asking my guests, Darrell S. Pardi, M.D., and Laura E. Raffals, M.D., both gastroenterologists at the Mayo Clinic. We'll be discussing “Microscopic Colitis” as part of our ongoing series of podcasts on “Inflammatory Bowel Disease”. https://ce.mayo.edu/content/mayo-clinic-talks-inflammatory-bowel-disease Connect with us and learn more here: https://ce.mayo.edu/online-education/content/mayo-clinic-podcasts 

Dr. Hao Nguyen presents focal therapy as a promising treatment option for carefully selected prostate cancer patients, especially those with intermediate-risk, localized disease. Unlike whole-gland treatments, focal therapy targets only the tumor while preserving healthy tissue, reducing the risk of side effects like urinary or sexual dysfunction. UCSF offers multiple approaches—high-intensity focused ultrasound, cryotherapy, and irreversible electroporation—selected based on tumor location and anatomy. Dr. Nguyen emphasizes the importance of precise imaging, MRI fusion biopsy, and genomic testing for patient selection and treatment planning. Early outcomes show encouraging results, with most patients avoiding surgery or radiation within two years and maintaining quality of life. While not yet standard first-line care, focal therapy is gaining traction through research and expert consensus. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40804]

Dr. Hao Nguyen presents focal therapy as a promising treatment option for carefully selected prostate cancer patients, especially those with intermediate-risk, localized disease. Unlike whole-gland treatments, focal therapy targets only the tumor while preserving healthy tissue, reducing the risk of side effects like urinary or sexual dysfunction. UCSF offers multiple approaches—high-intensity focused ultrasound, cryotherapy, and irreversible electroporation—selected based on tumor location and anatomy. Dr. Nguyen emphasizes the importance of precise imaging, MRI fusion biopsy, and genomic testing for patient selection and treatment planning. Early outcomes show encouraging results, with most patients avoiding surgery or radiation within two years and maintaining quality of life. While not yet standard first-line care, focal therapy is gaining traction through research and expert consensus. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40804]

Dr. Hao Nguyen presents focal therapy as a promising treatment option for carefully selected prostate cancer patients, especially those with intermediate-risk, localized disease. Unlike whole-gland treatments, focal therapy targets only the tumor while preserving healthy tissue, reducing the risk of side effects like urinary or sexual dysfunction. UCSF offers multiple approaches—high-intensity focused ultrasound, cryotherapy, and irreversible electroporation—selected based on tumor location and anatomy. Dr. Nguyen emphasizes the importance of precise imaging, MRI fusion biopsy, and genomic testing for patient selection and treatment planning. Early outcomes show encouraging results, with most patients avoiding surgery or radiation within two years and maintaining quality of life. While not yet standard first-line care, focal therapy is gaining traction through research and expert consensus. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40804]

Dr. Hao Nguyen presents focal therapy as a promising treatment option for carefully selected prostate cancer patients, especially those with intermediate-risk, localized disease. Unlike whole-gland treatments, focal therapy targets only the tumor while preserving healthy tissue, reducing the risk of side effects like urinary or sexual dysfunction. UCSF offers multiple approaches—high-intensity focused ultrasound, cryotherapy, and irreversible electroporation—selected based on tumor location and anatomy. Dr. Nguyen emphasizes the importance of precise imaging, MRI fusion biopsy, and genomic testing for patient selection and treatment planning. Early outcomes show encouraging results, with most patients avoiding surgery or radiation within two years and maintaining quality of life. While not yet standard first-line care, focal therapy is gaining traction through research and expert consensus. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40804]

UCSF oncologist Dr. Jonathan Chou discusses how genetics and genomics are transforming the diagnosis and treatment of prostate cancer. He explains how inherited and acquired mutations—especially in DNA repair genes like BRCA2—can impact both cancer risk and treatment decisions. Dr. Chou outlines how UCSF researchers use tumor and blood-based biopsies to identify key mutations and genomic features that help tailor care for each patient. Examples include how genomic scores can predict response to radiation and how targeted therapies like PARP inhibitors benefit patients with specific mutations. The talk highlights the growing role of precision medicine in guiding individualized treatment plans based on the unique genetic profile of each patient's cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40798]

UCSF oncologist Dr. Jonathan Chou discusses how genetics and genomics are transforming the diagnosis and treatment of prostate cancer. He explains how inherited and acquired mutations—especially in DNA repair genes like BRCA2—can impact both cancer risk and treatment decisions. Dr. Chou outlines how UCSF researchers use tumor and blood-based biopsies to identify key mutations and genomic features that help tailor care for each patient. Examples include how genomic scores can predict response to radiation and how targeted therapies like PARP inhibitors benefit patients with specific mutations. The talk highlights the growing role of precision medicine in guiding individualized treatment plans based on the unique genetic profile of each patient's cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40798]

UCSF oncologist Dr. Jonathan Chou discusses how genetics and genomics are transforming the diagnosis and treatment of prostate cancer. He explains how inherited and acquired mutations—especially in DNA repair genes like BRCA2—can impact both cancer risk and treatment decisions. Dr. Chou outlines how UCSF researchers use tumor and blood-based biopsies to identify key mutations and genomic features that help tailor care for each patient. Examples include how genomic scores can predict response to radiation and how targeted therapies like PARP inhibitors benefit patients with specific mutations. The talk highlights the growing role of precision medicine in guiding individualized treatment plans based on the unique genetic profile of each patient's cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40798]

Episode 72 - VERITAS - CT vs. Scope Lung Biopsy Showdown by AABIP

How do the experts balance organ preservation, oncologic control, and emerging therapies in both localized and metastatic cases of penile cancer? This episode of BackTable Tumor Board focuses on penile cancer diagnosis and treatment, featuring urologic oncologist Dr. Charles Peyton (UAB), radiation oncologist Dr. Juanita Crook (UBC), and medical oncologist Dr. Andrea Apolo (NCI). --- This podcast is supported by:Ferring Pharmaceuticals --- SYNPOSIS This session covers case studies ranging from localized to advanced penile cancer, diagnostic practices, imaging preferences (MRI vs. CT), and treatment options, including surgery, brachytherapy, chemoradiation, and neoadjuvant chemotherapy. The multidisciplinary team highlights the complexities of treating this rare cancer, underscores the importance of physical exams, and stresses the necessity of personalized treatment plans. They also delve into the challenges of managing metastatic stages, potential salvage therapies, and the importance of clinical trials in enhancing treatment efficacy. The doctors also emphasize the potential of immunotherapy and chemotherapy combinations for metastatic disease. --- TIMESTAMPS 00:00 - Introduction02:23 - Imaging Preferences03:29 - Biopsy vs Immediate Surgery06:04 - Lymph Node Dissection vs Radiation13:48 - Brachytherapy Techniques and Case Study23:21 - Challenges in Advanced Penile Cancer27:03 - Chemotherapy and Chemoradiation30:15 - InPACT Trial37:12 - Salvage Therapies and Exploring New Treatment Frontiers44:25 - Support and Awareness for Penile Cancer51:29 - Final Thoughts --- RESOURCES Society of Urologic Oncologyhttps://suonet.org/home.aspx

In the final part of this three-part series, Dr. Justin Abbatemarco and Dr. Sumanth Reddy discuss his team's findings on the treatment approach presented in this paper.  Show reference: https://www.neurology.org/doi/10.1212/NXI.0000000000200397  

In part two of this three-part series, Dr. Justin Abbatemarco and Dr. Sumanth Reddy discuss how patients with amyloid-beta–related angiitis present.  Show reference: https://www.neurology.org/doi/10.1212/NXI.0000000000200397   

This episode of the podcast welcomes Dr. Kelly Keating, DACVP, DACVD. Dr. Keating sees clinical dermatology cases in Las Vegas and reviews dermatopathology. So, she has experience collecting the biopsy samples herself and reading them!Dr. Keating provides insight on how to maximize your histopathology findings and work with your dermatopathologist to get a diagnosis. Nobody wants to get back non-specific inflammation!You can go to https://www.animaldermatology.com/dermatopathology-services if you are interested in submitting to Animal Dermatopathology Services!TIMESTAMPS00:00 Intro01:13 Most common mistakes you see with submissions to skin biopsy?04:46 How much does having a submission of history help you when you do get a sample?09:21 Tips for general practitioners who are submitting biopsies12:04 Tips for mass removals14:46 Site selection18:28 Biopsy an ulcer20:14 Preferred withdrawal time24:25 How often do you see infections covering up what you need to see?27:40 What are special stains?30:05 Tissue Culture explanation 33:18 Biopsy Ear Tips35:10 Where people can send Dr. Keating samples36:47 Outro

In part one of this three-part series, Dr. Justin Abbatemarco and Dr. Sumanth Reddy discuss small vessel primary CNS vasculitis. Show reference: https://www.neurology.org/doi/10.1212/NXI.0000000000200397 

Dr. Justin Abbatemarco talks with Drs. Sumanth Reddy and Jeffrey Gelfand about the complexities of small vessel predominant primary CNS vasculitis, clinical features, and the impact of early intensive immunosuppressive therapy on remission.  Read the related article in Neurology® Neuroimmunology & Neuroinflammation.  Disclosures can be found at Neurology.org.